Table Info

Table 1.

HLA class I alleles used, ordered by their global frequencies in descending order (see text for details)

Gene A		Gene B		Gene C
Allele	Frequency	Allele	Frequency	Allele	Frequency
A02:01*	0.19257	B07:02*	0.08271	C04:01*	0.13265
A01:01*	0.10933	B08:01*	0.06555	C07:02*	0.12442
A24:02*	0.09998	B35:01*	0.05815	C07:01*	0.12235
A03:01*	0.09324	B44:02*	0.05244	C06:02*	0.08360
A11:01*	0.07282	B44:03*	0.04972	C04:43*	0.08053
A23:01*	0.03373	B51:01*	0.04963	C03:04*	0.06754
A68:01*	0.03305	B40:01*	0.04177	C05:01*	0.05914
A26:01*	0.03199	B15:01*	0.03966	C01:02*	0.04659
A29:02*	0.02847	B18:01*	0.03814	C02:02*	0.04371
A32:01*	0.02784	B14:02*	0.02643	C16:01*	0.04129
A31:01*	0.02769	B57:01*	0.02553	C12:03*	0.03938
A68:02*	0.01941	B53:01*	0.02361	C08:02*	0.03282
A02:06*	0.01365	B58:01*	0.02326	C15:02*	0.02997
A33:01*	0.01282	B27:05*	0.02240	C17:01*	0.01957
A25:01*	0.01255	B13:02*	0.02061	C14:02*	0.01949
A02:02*	0.01097	B40:02*	0.01981	C08:01*	0.01833
A02:05*	0.01065	B38:01*	0.01872	C12:02*	0.01678
		B49:01*	0.01844	C03:02*	0.01492
		B35:03*	0.01644	C07:04*	0.01196
		B45:01*	0.01291	C17:03*	0.01037
		B15:03*	0.01247
		B46:01*	0.01204
		B37:01*	0.01181
		B39:01*	0.01011

Supplementary materials

The supplementary materials for this article are available at: https://www.explorationpub.com/uploads/Article/file/10033_sup_1.pdf.

Declarations

Author contributions

SAC and APG contributed to data analysis; SAC, EPT and APG contributed to writing the manuscript.

Conflicts of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Partial funding for this study was provided by the University of Minnesota (the American Legion Brain Sciences Chair) and the U.S. Department of Veterans Affairs. The sponsors had no role in the current study design, analysis or interpretation, or in the writing of this paper. The contents do not represent the views of the U.S. Department of Veterans Affairs or the United States Government.

Copyright

References

Sanchez-Mazas A, Lemaître JF, Currat M. Distinct evolutionary strategies of human leucocyte antigen loci in pathogen-rich environments. Philos Trans R SocLond B Biol Sci. 2012;367:830–9. [DOI]

Salamon H, Klitz W, Easteal S, Gao X, Erlich HA, Fernandez-Viña M, et al. Evolution of HLA class II molecules: allelic and amino acid site variability across populations. Genetics. 1999;152:393–400. [PubMed] [PMC]

Charonis S, Tsilibary EP, Georgopoulos AP. SARS-CoV-2 virus and Human Leukocyte Antigen (HLA) Class II: investigation of binding affinities for COVID-19 protection and vaccine development. J Immunological Sci. 2020;4:12–23. [DOI]

Charonis S, James LM, Georgopoulos AP. In silico assessment of binding affinities of three dementia-protective Human Leukocyte Antigen (HLA) alleles to nine human herpes virus antigens. Curr Res Transl Med. 2020;68:211–6. [DOI] [PubMed]

The allele frequence database [Internet]. Liverpool: Royal Liverpool University Hospital; c2019 [updated 2019 Jul 10; cited 2020 Jun 16]. Available from: http://www.allelefrequencies.net/

Consortium U. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Res. 2019;47:D506–15. [DOI] [PubMed] [PMC]

Immune epitope database and analysis [Internet]. Bethesda: the National Institutes of Health (NIH), National Institute of Allergy and Infectious Disease (NIAID); c2020 [cited 2020 Jun 16]. Available from: http://www.iedb.org

Reynisson B, Alvarez B, Paul S, Peters B, Nielsen M. NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data. Nucleic Acids Res. 2020;48:W449–54. [DOI] [PubMed] [PMC]

Duan L, Zheng Q, Zhang H, Niu Y, Lou Y, Wang H. The SARS-CoV-2 spike glycoprotein biosynthesis, structure, function, and antigenicity: implications for the design of spike-based vaccine immunogens. Front Immunol. 2020;11:576622. [DOI] [PubMed] [PMC]

10.

Grifoni A, Sidney J, Zhang Y, Scheuermann RH, Peters B, Sette A. A sequence homology and bioinformatic approach can predict candidate targets for immune responses to SARS-CoV-2. Cell Host Microbe. 2020;27:671–80.e2. [DOI] [PubMed] [PMC]

11.

Ahmed SF, Quadeer AA, McKay MR. Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies. Viruses. 2020;12:254. [DOI]

12.

Nguyen A, David JK, Maden SK, Wood MA, Weeder BR, Nellore A, et al. Human leukocyte antigen susceptibility map for severe acute respiratory syndrome coronavirus 2. J Virol. 2020;94:e00510–20. [DOI] [PubMed] [PMC]

13.

Nelde A, Bilich T, Heitmann JS, Maringer Y, Salih HR, Roerden M, et al. SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition. Nat Immunol. 2021;22:74–85. [DOI] [PubMed]

14.

Jain V, Yuan JM. Predictive symptoms and comorbidities for severe COVID-19 and intensive care unit admission: a systematic review and meta-analysis. Int J Public Health. 2020;65:533–46. [DOI] [PubMed] [PMC]

15.

Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, et al.; China Medical Treatment Expert Group for COVID-19. Comorbidity and its impact on 1,590 patients with COVID-19 in China: a nationwide analysis. EurRespir J. 2020;55:2000547. [DOI]